Compositions and methods of enhancing immune responses
AssigneesThe Texas A&M University System, Board of Trustees of the University of Arkansas
InventorsWalter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton
Life of this patent
Estimating the term…
Abstract
Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.
Claims24
A vaccine vector comprising at least two antigenic polynucleotides, wherein a first antigenic polynucleotide encodes SEQ ID NO:
- 5 and a second antigenic polynucleotide encodes SEQ ID NO:
- 20, and wherein the first antigenic polynucleotide is inserted in the same reading frame into a first transmembrane polynucleotide encoding an external portion of a transmembrane protein and the second antigenic polynucleotide is inserted in the same reading frame into a second transmembrane polynucleotide encoding an external portions of a transmembrane protein.
A vaccine vector comprising a first polynucleotide encoding a polypeptide of SEQ ID NO:
- 8 or SEQ ID NO:
- 9, wherein the polynucleotide is inserted into a second polynucleotide in the vaccine vector encoding an external portion of a transmembrane protein in the same reading frame as the polynucleotide encoding the transmembrane protein.
A vaccine vector comprising at least two antigenic polynucleotides, wherein a first antigenic polynucleotide encodes an M2e polypeptide, and a second antigenic polynucleotide encodes a hemagglutinin polypeptide, wherein the first antigenic polynucleotide is inserted in the same reading frame into a first transmembrane polynucleotide sequence encoding an external portion of a transmembrane protein and the second antigenic polynucleotides are inserted in the same reading frame into a second transmembrane polynucleotide sequences encoding an external portion of a transmembrane protein, and wherein the vaccine vector enhances the immune response of a subject to Influenza A.
A vaccine vector comprising a CD154 polynucleotide sequence encoding a CD154 polypeptide having fewer than 50 amino acids and comprising amino acids 140-149 of SEQ ID NO:
- 26 or a homolog thereof, wherein the CD154 polynucleotide is inserted into a polynucleotide encoding an external portion of a transmembrane protein in the same reading frame as the polynucleotide encoding the transmembrane protein and the CD154 polypeptide is expressed on the surface of the vaccine vector.
Dependencies are inferred from the claim text.